The ubiquitin-proteasome system in prostate cancer and its transition to castration resistance

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 6, 2012, Pages 752-761

  Voutsadakis, Ioannis A ^a   Papandreou, Christos N ^a  

^a UNIVERSITY HOSPITAL OF LARISSA   (Greece)

Author keywords

Androgens; Castration resistance; Prostate cancer; Proteasome; Transcription factors; Ubiquitin

Indexed keywords

ANDROGEN RECEPTOR; APC PROTEIN; BETA CATENIN; BORTEZOMIB; BRCA2 PROTEIN; CATENIN; CCAAT ENHANCER BINDING PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; DEATH RECEPTOR 5; FK 506 BINDING PROTEIN; FOCAL ADHESION KINASE; MITOXANTRONE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEASOME; PROTEIN ARGININE METHYLTRANSFERASE; T CELL FACTOR PROTEIN; TETRATRICOPEPTIDE REPEAT PROTEIN; UBIQUITIN; UBIQUITIN CONJUGATING ENZYME E2; UBIQUITIN PROTEIN LIGASE E3;

3' UNTRANSLATED REGION; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CASTRATION RESISTANT PROSTATE CANCER; FLUORESCENCE IMAGING; HUMAN; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TRANSCRIPTION REGULATION; UBIQUITINATION;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 84870499734     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.03.013     Document Type: Review

References (122)

1. Delongchamps N.B., Singh A., Haas G.P. The role of prevalence in the diagnosis of prostate cancer. Cancer Control 2006, 13:158-168.
2. Sakr W.A., Grignon D.J., Crissman J.D., et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20 and 69: An autopsy study of 249 cases. In Vivo 1994, 8:439-444.
3. Loblaw D.A., Virgo K.S., Nam R., et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2007 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007, 25:1596-1605.
4. de Leval J., Boca P., Yousef E., et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: Results of a prospective randomized multicenter trial. Clin Prostate Cancer 2002, 1:163-171.
5. Patterson S.G., Balducci L., Pow-Sang J.M. Controversies surrounding androgen deprivation for prostate cancer. Cancer Control 2002, 9:315-325.
6. Horwich A., Huddart R.A., Gadd J., et al. A pilot study of intermittent androgen deprivation in advanced prostate cancer. Br J Urol 1998, 81:96-99.
7. Feldman B.J., Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001, 1:34-45.
8. Yeh S., Lin H.-K., Kang H.-Y., et al. From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 1999, 96:5458-5463.
9. Nazareth L.V., Weigel N.L. Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem 1996, 271:19900-19907.
10. Marcelli M., Ittmann M., Mariani S., et al. Androgen receptor mutations in prostate cancer. Cancer Res 2000, 60:944-949.
11. Koivisto P., Kononen J., Palmberg C., et al. Androgen receptor gene amplification: A possible molecular mechanism of androgen deprivation therapy failure in prostate cancer. Cancer Res 1997, 57:314-319.
12. Wen Y., Hu M.C.-T., Makino K., et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the akt pathway. Cancer Res 2000, 60:6841-6845.
13. Mani A., Gelmann E.P. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 2005, 23:4776-4789.
14. Almond J.B., Cohen G.M. The proteasome: A novel target for cancer chemotherapy. Leukemia 2002, 16:433-443.
15. Voutsadakis I.A. Pathogenesis of colorectal carcinoma and therapeutic implications: The roles of the ubiquitin-proteasome system and Cox-2. J Cell Mol Med 2007, 11:252-285.
16. Wolf D.H., Hilt W. The proteasome: A proteolytic nanomachine of cell regulation and waste disposal. Biochim Biophys Acta 2004, 1695:19-31.
17. Rechsteiner M. The 26S Proteasome. Protein degradation 2005, 220-247. Wiley-VCH Verlag, Weinheim. R.J. Mayer, A. Ciechanover, M. Rechsteiner (Eds.).
18. Vodermaier H.C. APC/C and SCF: Controlling each other and the cell cycle. Curr Biol 2004, 14:R787-R796.
19. Hershko A. Mechanisms and regulation of the degradation of cyclin B. Phil Trans R Soc London B 1999, 354:1571-1576.
20. Sun X.-M., Butterworth M., MacFarlane M., et al. Caspase activation inhibits proteasome function during apoptosis. Mol Cell 2004, 14:81-93.
21. Adrain C., Creagh E.M., Cullen S.P., et al. Caspase-dependent inactivation of proteasome function during programmed cell death in drosophila and man. J Biol Chem 2004, 279:36923-36930.
22. Friedman J., Xue D. To live or die by the sword: The regulation of apoptosis by the proteasome. Dev Cell 2004, 7:460-461.
23. Li B., Dou Q.P. Bax degradation by the ubiquitin/proteasome-dependent pathway: Involvement in tumor survival and progression. Proc Natl Acad Sci USA 2000, 97:3850-3855.
24. Zoubeidi A., Zardan A., Beraldi E., et al. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res 2007, 67:10455-10465.
25. Buchanan G., Ricciardelli C., Harris J.M., et al. Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine-rich tetratricopeptide repeat containing protein α. Cancer Res 2007, 67:10087-10096.
26. Yong W., Yang Z., Periyasamy S., et al. Essential role for co-chaperone Fkbp52 but not Fkbp51 in androgen receptor-mediated signaling and physiology. J Biol Chem 2007, 282:5026-5036.
27. Hassan S., Biswas M.H.U., Zhang C., et al. Heat shock protein 27 mediates repression of androgen receptor function by protein kinase D1 in prostate cancer cells. Oncogene 2009, 28:4386-4396.
28. Nelson P.S., Clegg N., Arnold H., et al. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci USA 2002, 99:11890-11895.
29. Huang W., Shostak Y., Tarr P., et al. Cooperative assembly of androgen receptor into a nucleoprotein complex that regulates the prostate-specific antigen enhancer. J Biol Chem 1999, 274:25756-25768.
30. Claessens F., Denayer S., Van Tilborgh N., et al. Diverse roles of androgen receptor (AR) domains in AR-mediated signaling. Nuclear Receptor Signaling 2008, 6:e008.
31. Moore S.M., Nelson P.S. Gene expression profiling of the human prostate androgen response program. J Androl 2002, 23:163-169.
32. Holzbeierlein J., Lal P., LaTulippe E., et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004, 164:217-227.
33. Chandra S., Shao J., Li J.X., et al. A common motif targets Huntingtin and the androgen receptor to the proteasome. J Biol Chem 2008, 283:23950-23955.
34. Jaworski T. Degradation and beyond: Control of androgen receptor activity by the proteasome system. Cell Mol Biol Lett 2006, 11:109-131.
35. Voutsadakis I.A. PPARγ and colorectal carcinogenesis. J Cancer Res Clin Oncol 2007, 133:917-928.
36. Kinyamu H.K., Chen J., Archer T.K. Linking the ubiquitin-proteasome pathway to chromatin remodeling/modification by nuclear receptors. J Mol Endocrinol 2005, 34:281-297.
37. Kinyamu H.K., Jefferson W.N., Archer T.K. Intersection of nuclear receptors and the proteasome on the epigenetic landscape. Environ Mol Mutagen 2008, 49:83-95.
38. Rochette-Egly C. Dynamic combinatorial networks in nuclear receptor-mediated transcription. J Biol Chem 2005, 280:32565-32568.
39. Lonard D.M., Lanz R.B., O'Malley B.W. Nuclear receptor co-regulators and human disease. Endocr Rev 2007, 28:575-587.
40. Chen P.-H., Tsao Y.-P., Wang C.-C., et al. Nuclear receptor interaction protein, a coactivator of androgen receptors (AR), is regulated by AR and Sp1 to feed forward and activate its own gene expression through AR protein stability. Nucleic Acids Res 2008, 36:51-66.
41. Jenster G., Spencer T.E., Burcin M.M., et al. Steroid receptor induction of gene transcription: A two-step model. Proc Natl Acad Sci USA 1997, 94:7879-7884.
42. Zhang Y. Transcriptional regulation by histone ubiquitination and de-ubiquitination. Genes Dev 2003, 17:2733-2740.
43. Dover J., Schneider J., Tawiah-Boateng M.A., et al. Methylation of histone H3 by COMPASS requires ubiquitination of histone H2B by Rad6. J Biol Chem 2002, 277:28368-28371.
44. Sun Z.W., Allis C.D. Ubiquitination of histone H2B regulates H3 methylation and gene silencing in yeast. Nature 2002, 418:104-108.
45. Laribee R.N., Fuchs S.M., Strahl B.D. H2B ubiquitination in transcriptional control: A FACT-finding mission. Genes Dev 2007, 21:737-743.
46. Ezhkova E., Tansey W.P. Proteasomal ATPases link ubiquitylation of histone H2B to methylation of histone H3. Mol Cell 2004, 13:435-442.
47. Logan I.R., Gaughan L., McCracken S.R.C., et al. Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer. Mol Cell Biol 2006, 26:6502-6510.
48. Boeger H., Bushnell D.A., Davis R., et al. Structural basis of eukaryotic gene transcription. FEBS Lett 2005, 579:899-903.
49. Boeger H., Griesenbeck J., Strattan J.S., et al. Removal of promoter nucleosomes by disassembly rather than sliding in vivo. Mol Cell 2004, 14:667-673.
50. Perissi V., Scafoglio C., Zhang J., et al. TBL1 and TBLR1 phosphorylation on regulated gene promoters overcomes dual CtBP and NCoR/SMRT transcriptional repression checkpoints. Mol Cell 2008, 29:755-766.
51. Gaughan L., Logan I.R., Neal D.E., et al. Regulation of androgen receptor and histone deacetylase 1 by mdm2-mediated ubiquitylation. Nucleic Acids Res 2005, 33:13-26.
52. Ramamoorthy S., Nawaz Z. E6-associated protein (E6-AP) is a dual function coactivator of steroid hormone receptors. Nuclear Receptor Signaling 2008, 6:e006.
53. Vijayvargia R., May M.S., Fondell J.D. A co-regulatory role for the mediator complex in prostate cancer cell proliferation and gene expression. Cancer Res 2007, 67:4034-4041.
54. Conaway R.C., Brower C.S., Conaway J.W. Emerging roles of ubiquitin in transcriptional regulation. Science 2002, 296:1254-1258.
55. Burgdorf S., Leister P., Scheidtmann K.H. TSG101 interacts with apoptosis-antagonizing transcription factor and enhances androgen receptor-mediated transcription by promoting its mono-ubiquitination. J Biol Chem 2004, 279:17524-17534.
56. Kang Z., Pirskanen A., Jänne O.A., et al. Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex. J Biol Chem 2002, 277:48366-48371.
57. Tyagi R.K., Lavrovsky Y., Ahn S.C., et al. Dynamics of intracellular movement and nucleocytoplasmic recycling of the ligand-activated androgen receptor in living cells. Mol Endocrinol 2000, 14:1162-1174.
58. Page S.T., Lin D.W., Mostaghel E.A., et al. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 2006, 91:3850-3856.
59. Moehler J.L., Gregory C.W., Ford O.H., et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004, 10:440-448.
60. Harris W.P., Mostaghel E.A., Nelson P.S., et al. Androgen deprivation therapy: Progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009, 6:76-85.
61. Pienta K.J., Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006, 12:1665-1671.
62. Balk S.P., Knudsen K.E. AR, the cell cycle, and prostate cancer. Nuclear Receptor Signaling 2008, 6:e001.
63. Chen C.D., Welsbie D.S., Tran C., et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004, 10:33-39.
64. Gregory C.W., He B., Johnson R.T., et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001, 61:4315-4319.
65. Shah R.B., Mehra R., Chinnaiyan A.M., et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program. Cancer Res 2004, 64:9209-9216.
66. Gregory C.W., Johnson R.T., Mohler J.L., et al. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001, 61:2892-2898.
67. Nanus D.M. Of peptides and peptidases: The role of cell surface peptidases in cancer. Clin Cancer Res 2003, 9:6307-6309.
68. Sumitomo M., Shen R., Nanus D.M. Involvement of neutral endopeptidase in neoplastic progression. Biochim Biophys Acta 2005, 1751:52-59.
69. Pinet F. À quoi sert le système endothéline?. Med Sci 2004, 20:339-345.
70. Papandreou C.N., Usmani B., Geng Y., et al. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med 1998, 4:50-57.
71. Osman I., Dai J., Mikhail M., et al. Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression. Cancer 2006, 107:2628-2636.
72. Shen R., Dai J., Sumitomo M., et al. Identification and characterization of two androgen response regions in the human neutral endopeptidase gene. Mol Cell Endocrinol 2000, 170:131-142.
73. Shen R., Sumitomo M., Dai J., et al. Androgen-induced growth inhibition of androgen receptor expressing androgen-independent prostate cancer cells is mediated by increased levels of neutral endopeptidase. Endocrinol 2000, 141:1699-1704.
74. Levine L., Lucci J.A., Pazdrak B., et al. Bombesin stimulates nuclear factor κB activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res 2003, 63:3495-3502.
75. Sumitomo M., Shen R., Walburg M., et al. Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling. J Clin Invest 2000, 106:1399-1407.
76. Sumitomo M., Iwase A., Zheng R., et al. Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN. Cancer Cell 2004, 5:67-78.
77. Sumitomo M., Asano T., Asakuma J., et al. Chemosensitization of androgen-independent prostate cancer with neutral endopeptidase. Clin Cancer Res 2004, 10:260-266.
78. Patrikidou A, Voutsadakis IA, Karagiannaki A, et al. Inverse relationship between NEP expression, proteasomal activity and NF-κB activation in androgen-dependent and independent prostate cancer, with evidence of existence of a neuropeptide-inducible link. Proceedings of the ASCO Genitourinary Cancers Symposium, San Francisco, CA, February, 2008. p.134 [Abstract 78].
79. Srivastava J., Procyk K.J., Iturrioz X., et al. Phosphorylation is required for PMA- and cell-cycle-induced degradation of protein kinase Cδ. Biochem J 2002, 368:349-355.
80. Adachi M., Katsumura K.R., Fujii K., et al. Proteasome-dependent decrease in Akt by growth factors in vascular smooth muscle cells. FEBS Lett 2003, 554:77-80.
81. Dai J., Shen R., Sumitomo M., et al. Synergistic activation of the androgen receptor by bombesin and low-dose androgen. Clin Cancer Res 2002, 8:2399-2405.
82. Osman I., Yee H., Taneja S.S., et al. Neutral endopeptidase protein expression and prognosis in localized prostate cancer. Clin Cancer Res 2004, 10:4096-4100.
83. Santer F.R., Bacher N., Moser B., et al. Nuclear insulin-like growth factor binding protein-3 induces apoptosis and is targeted to ubiquitin/proteasome-dependent proteolysis. Cancer Res 2006, 66:3024-3033.
84. Gur G., Rubin C., Katz M., et al. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J 2004, 23:3270-3281.
85. Moro L., Arbini A.A., Marra E., et al. Up-regulation of Skp2 after prostate cancer cell adhesion to basement membranes results in BRCA2 degradation and cell proliferation. J Biol Chem 2006, 281:22100-22107.
86. Carano A.C., Pagano M. Role of the F-Box protein Skp2 in adhesion-dependent cell cycle progression. J Cell Biol 2001, 153:1381-1389.
87. Friedberg E.C. How nucleotide excision repair protects against cancer. Nat Rev Cancer 2001, 1:22-33.
88. Huang H., Regan K.M., Wang F., et al. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci USA 2005, 102:1649-1654.
89. Yang G., Ayala G., De Marzo A., et al. Elevated Skp2 protein expression in human prostate cancer: Association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res 2002, 8:3419-3426.
90. Shim E.-H., Johnson L., Noh H.-L., et al. Expression of the F-Box protein SKP2 induces hyperplasia, dysplasia, and low-grade carcinoma in the mouse prostate. Cancer Res 2003, 63:1583-1588.
91. Hsu T., Trojanowska M., Watson D.K. Ets proteins in biological control and cancer. J Cell Biochem 2004, 91:896-903.
92. Oettgen P. Regulation of vascular inflammation and remodeling by ETS factors. Circ Res 2006, 99:1159-1166.
93. Tomlins S.A., Rhodes D.R., Perner S., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
94. Mehra R., Tomlins S.A., Shen R., et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007, 20:538-544.
95. Massie C.E., Adryan B., Barbosa-Morais N.L., et al. New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep 2007, 8:871-878.
96. Ilyas M. Wnt signaling and the mechanistic basis of tumor development. J Pathol 2005, 205:130-144.
97. Yang F., Li X., Sharma M., et al. Linking β-catenin to androgen-signaling pathway. J Biol Chem 2002, 277:11336-11344.
98. Schweizer L., Rizzo C.A., Spires T.E., et al. The androgen receptor can signal through Wnt/β-catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens. BMC Cell Biol 2008, 9:4.
99. Zoubeidi A., Chi K., Gleave M. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res 2010, 16:1088-1093.
100. Rocchi P., So A., Kojima S., et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 2004, 64:6595-6602.
101. Miyake H., Nelson C., Rennie P.S., et al. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 2000, 60:170-176.
102. Parcellier A., Schmitt E., Gurbuxani S., et al. HSP27 is a ubiquitin-binding protein involved in I-κB proteasomal degradation. Mol Cell Biol 2003, 23:5790-5802.
103. Zoubeidi A., Ettinger S., Beraldi E., et al. Clusterin facilitates COMMD1 and I-κB degradation to enhance NF-κB activity in prostate cancer cells. Mol Cancer Res 2010, 8:119-130.
104. Papandreou C.N., Logothetis C.J. Bortezomib as a potential treatment for prostate cancer. Cancer Res 2004, 64:5036-5043.
105. Richardson P.G., Hideshima T., Anderson K.C. Bortezomib (PS-341): A novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 2003, 10:361-369.
106. Ikezoe T., Yang Y., Saito T., et al. Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells. Cancer Sci 2004, 95:271-275.
107. Thorpe P.A., Christian P.A., Schwarze S.R. Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis. Prostate 2008, 68:200-209.
108. Lin H.-K., Altuwaijri S., Lin W.-J., et al. Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with co-regulators in prostate cancer cells. J Biol Chem 2002, 277:36570-36576.
109. Vu H.-Y., Juvekar A., Ghosh C., et al. Proteasome inhibitors induce apoptosis of prostate cancer cells by inducing nuclear translocation of IκBα. Arch Biochem Biophys 2008, 475:156-163.
110. Huang Y.-T., Pan S.-L., Guh J.-H., et al. YC-1 suppresses constitutive nuclear factor-κB activation and induces apoptosis in human prostate cancer cells. Mol Cancer Ther 2005, 4:1628-1635.
111. Li W., Zhang X., Olumi A.F. MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L). Cancer Res 2007, 67:2247-2255.
112. Lashinger L.M., Zhu K., Williams S.A., et al. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Res 2005, 65:4902-4908.
113. Nikrad M., Johnson T., Puthalalath H., et al. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther 2005, 4:443-449.
114. Kandasamy K., Kraft A.S. Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region. Mol Cancer Ther 2008, 7:1091-1100.
115. Yoshida T., Shiraishi T., Nakata S., et al. Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. Cancer Res 2005, 65:5662-5667.
116. Williams S., Pettaway C., Song R., et al. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2003, 2:835-843.
117. Papandreou C.N., Daliani D.D., Nix D., et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004, 22:2108-2121.
118. Dreicer R., Petrylak D., Agus D., et al. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Cancer Res 2007, 13:1208-1215.
119. Meluch A.A., Spigel D.S., Greco F.A., et al. Weekly docetaxel and bortezomib in the treatment of patients with advanced hormone refractory prostate cancer (HRPC): A Minnie Pearl Cancer Research Network Phase II trial. J Clin Oncol 2005, 23:436s. [Abstract 4735].
120. Siefker-Radtke A.O., Poulter V., Mathew P., et al. Preliminary evidence of efficacy and tolerance for weekly intravenous bortezomib plus mitoxantrone in patients with advanced androgen-independent prostate cancer (AIPCa). J Clin Oncol 2005, 23:394s. [Abstract 4567].
121. Woodham C., Birch L., Prins G.S. Neonatal estrogen down-regulates prostatic androgen receptor through a proteasome-mediated protein degradation pathway. Endocrinol 2003, 144:4841-4850.
122. Sakamoto K.M., Kim K.B., Verma R., et al. Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation. Mol Cell Proteomics 2003, 2:1350-1358.